Vor Biopharma Inc. (NASDAQ:VOR) Receives $42.25 Average PT from Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has been given an average rating of “Moderate Buy” by the eleven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $42.25.

A number of brokerages recently commented on VOR. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush boosted their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th.

Institutional Trading of Vor Biopharma

A number of large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. boosted its holdings in Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. grew its position in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Vor Biopharma in the fourth quarter worth $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma in the fourth quarter worth $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma in the fourth quarter worth $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Up 0.9%

Shares of VOR stock opened at $23.59 on Friday. Vor Biopharma has a 52-week low of $6.50 and a 52-week high of $50.20. The company has a 50-day simple moving average of $18.00 and a two-hundred day simple moving average of $15.88.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities research analysts predict that Vor Biopharma will post -2.51 earnings per share for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).